Feb 29, 2008 by Brian Orelli, PhDRNAi Works -- MaybeAlnylam presents proof of concept, but where's the proof that it cures a disease?
Feb 28, 2008 by Brian Orelli, PhDMylan Almost Triples Revenue -- Big DealExtrinsic growth isn't all it's cracked up to be.
Feb 28, 2008 by Brian Orelli, PhDBenefiting From 2008's Generic DrugsWinners and losers of drugs going off patent this year.
Feb 27, 2008 by Brian Orelli, PhDBABY's Growing PainsFive acquisitions in three years will do that to a company.
Feb 27, 2008 by Brian Orelli, PhDEveryone's Picking on Anemia DrugsBut our Foolish analyst is picking on the meta-analysis.
Feb 26, 2008 by Brian Orelli, PhDThe Less-Flashy Prostate Cancer TreatmentGTx shows off clinical trial data for a drug that counters the side effects of treatments.
Feb 26, 2008 by Brian Orelli, PhDQuick Take: Boston Scientific Gets Approved -- ThriceThree approvals in one day? Oh my.
Feb 25, 2008 by Brian Orelli, PhDLook Across the Pond for BiosimilarsTeva and others get positive recommendations for their new biosimilars.
Feb 25, 2008 by Brian Orelli, PhDThe Biologic That Keeps on GivingAbbott snags yet another FDA-approved use for Humira.
Feb 25, 2008 by Brian Orelli, PhDA Quest for ImprovementInvestors aren't impressed with Quest's short-term growth potential.
Feb 22, 2008 by Brian Orelli, PhDInverness' Rough TransitionInvestors aren't too happy about all the extrinsic growth.
Feb 22, 2008 by Brian Orelli, PhDSupreme Court Gives Health-Care Companies a BoostMedtronic is the immediate winner, but the industry wins in the long term.
Feb 22, 2008 by Brian Orelli, PhDGoogle in Your Medicine CabinetDoes Google have what the others don't as it moves one step closer to launching its health-care website?
Feb 21, 2008 by Brian Orelli, PhDOnyx's Double Dose of TroublePoor clinical trial data and a lack of profits hit the drugmaker hard.
Feb 21, 2008 by Brian Orelli, PhDWatson Gets Less GenericBranded sales are up while generics fall for the year.
Feb 20, 2008 by Brian Orelli, PhDAbbott's Copycat CombinationsFDA approval of a combination drug doesn't leave Merck trembling.
Feb 15, 2008 by Brian Orelli, PhDNot Everything Is Looking Up at SonoSiteLegal and research expenses drag its bottom line down.
